Teclistamab in relapsed and refractory multiple myeloma: patients characteristics from post marketing acces (acces precoce) in France

被引：0
|
作者：
Harel, Stephanie [1 ]
de Colella, Jean-Marc Schiano [2 ]
Sonntag, Cecile [3 ]
Cazaubiel, Titouan [4 ]
Garderet, Laurent [5 ]
Bouillie, Sylvie [6 ]
Javelot, Matthieu [7 ]
Vernet, Sophie [7 ]
Perrot, Aurore [8 ]
机构：
[1] St Louis Hosp, Immunohematol Dept, AP HP, Paris, France
[2] AMU, Inst Paoli Calmettes, CRCM, Marseille, France
[3] ICANS, Dept Hematol, Strasbourg, France
[4] CHU Bordeaux, Bordeaux, France
[5] Hop St Antoine, Serv Hematol & Therapie Cellulaire, AP HP, Paris, France
[6] Janssen Cilag France, Issy Les Moulineaux, France
[7] Med Affair Janssen Cilag France, Issy Les Moulineaux, France
[8] Inst Univ Canc Toulouse Oncopole, Toulouse, France
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-014
引用
收藏
页码：S40 / S41
页数：2
相关论文
共 50 条
  • [31] Teclistamab in Relapsed Refractory Multiple Myeloma: Multi-Institutional Real-World Study
    Mohan, Meera
    Shah, Nishi
    Luan, Danny
    Monge, Jorge
    Forsberg, Mark
    Bhatlapenumarthi, Vineel
    Balev, Metodi
    Patwari, Anannya
    Cheruvalath, Heloise
    Bhutani, Divaya
    Thanendrarajan, Sharmilan
    Dhakal, Binod
    Zangari, Maurizio
    Al Hadidi, Samer
    Cooper, Dennis L.
    Lentzsch, Suzanne
    van Rhee, Frits
    D'Souza, Anita
    Szabo, Aniko
    Schinke, Carolina
    Chakraborty, Rajshekhar
    BLOOD, 2023, 142
  • [32] Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study
    Mohan, Meera
    Monge, Jorge
    Shah, Nishi
    Luan, Danny
    Forsberg, Mark
    Bhatlapenumarthi, Vineel
    Balev, Metodi
    Patwari, Anannya
    Cheruvalath, Heloise
    Bhutani, Divaya
    Thanendrarajan, Sharmilan
    Dhakal, Binod
    Zangari, Maurizio
    Al-Hadidi, Samer
    Cooper, Dennis
    Lentzsch, Suzanne
    van Rhee, Frits
    D'Souza, Anita
    Szabo, Aniko
    Schinke, Carolina
    Chakraborty, Rajshekhar
    BLOOD CANCER JOURNAL, 2024, 14 (01)
  • [33] Bendamustine in patients with relapsed or refractory multiple myeloma
    M Michael
    I Bruns
    E Bölke
    F Zohren
    A Czibere
    N N Safaian
    F Neumann
    R Haas
    G Kobbe
    R Fenk
    European Journal of Medical Research, 15
  • [34] Management of patients with relapsed/refractory multiple myeloma
    Ludwig, H.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 3 - 4
  • [35] Teclistamab Induces Favorable Responses in Patients with Relapsed and Refractory Multiple Myeloma after Prior BCMA-Directed Therapy
    Grajales-Cruz, Ariel F.
    Castaneda, Omar
    Hansen, Doris K.
    Vazquez-Martinez, Mariola A.
    Blue, Brandon
    Khadka, Sushmita
    Liu, Hien
    Ochoa-Bayona, Jose L.
    Freeman, Ciara Louise L.
    Locke, Frederick L.
    Nishihori, Taiga
    Shain, Kenneth
    Baz, Rachid
    Alsina, Melissa
    BLOOD, 2023, 142
  • [36] A Real-World Analysis of the Safety and Efficacy of Teclistamab for Patients with Relapsed/Refractory Multiple Myeloma and Baseline Renal Impairment
    Habib, Alma
    Khan, Abdullah Mohammad
    Laharwal, Mehak M.
    Mewawalla, Prerna
    Mckenna, Marshall
    Tiger, Yun Kyoung
    Shaikh, Hira
    Strouse, Christopher
    Green, Kimberly M.
    Davis, James A.
    Hashmi, Hamza
    Snyder, Jordan
    Mahmoudjafari, Zahra
    Mushtaq, Muhammad Umair
    Ahmed, Nausheen
    Abdallah, Al-Ola
    Atrash, Shebli
    Paul, Barry
    Friend, Reed
    BLOOD, 2024, 144 : 7037 - 7038
  • [37] Brazilian Single-Center Initial Experience and Safety of Teclistamab for Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma
    Lopes, Danielle Ovigli
    Kerbauy, Mariana
    Hamerschlak, Nelson
    Helman, Ricardo
    Arcuri, Leonardo
    Kerbauy, Lucila
    Ribeiro, Andreza
    Motta, Mariana
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S263 - S263
  • [38] Evaluating the efficacy of commercial teclistamab in relapsed refractory multiple myeloma patients with prior exposure to anti-BCMA therapies
    Firestone, Ross
    Shekarkhand, Tala
    Patel, Dhwani
    Tan, Carlyn Rose Co
    Hultcrantz, Malin
    Lesokhin, Alexander M.
    Mailankody, Sham
    Hassoun, Hani
    Shah, Urvi A.
    Korde, Neha
    Maclachlan, Kylee
    Landau, Heather Jolie
    Scordo, Michael
    Chung, David J.
    Shah, Gunjan L.
    Lahoud, Oscar Boutros
    Giralt, Sergio
    Usmani, Saad Zafar
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [39] Isatuximab with pomalidomide-dexamethasone in relapsed/refractory multiple myeloma: post-marketing surveillance in Japan
    Tagami, Nami
    Uchiyama, Michihiro
    Suzuki, Kenshi
    Shirai, Heigoroh
    Seto, Takeshi
    Nishina, Satoshi
    Iida, Shinsuke
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2024, 120 (02) : 217 - 228
  • [40] CLINICAL AND TREATMENT CHARACTERISTICS OF PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) IN EUROPE
    Oriol, A.
    Steinmetz, T.
    Patel, V
    Kutikova, L.
    Schmidt, N.
    Hennies, N.
    Thiess, A.
    Kostev, K.
    Leleu, X.
    VALUE IN HEALTH, 2019, 22 : S497 - S498
12345